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Abstract PK-120 is a substrate for plasma kallikrein (PK), 
recently purified from human plasma. Here we have established 
the cDNA sequence for human PK-120 mRNA. The deduced 
amino sequence of PK-120 revealed that it consists of 902 amino 
acid residues with a calculated mass of 116,423 Da. The putative 
cleavage sites by PK have been proposed, suggesting that PK-120 
may be a precursor of a bioactive peptide. Most interestingly, 
PK-120 showed significant sequence identities to heavy chains 
(HCs) of the inter-a-trypsin inhibitor (ITI) superfamily. 
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!. Introduction 
Plasma kallikrein (PK) is a serine protease in plasma, and 
plays key roles in the activation of the blood coagulation [1], 
fibrinolysis [2] and complement [3] systems, the release of 
bradykinin from high molecular weight kininogen [4], and the 
cellular responses of neutrophils [5-7]. These events eem to be 
induced through the limited proteolysis of protein substrates by 
PK. Recently, we purified a novel PK-sensitive protein from 
human plasma and characterized it [8]. This protein, named 
PK-120, is a single-chain glycoprotein of 120 kDa and contains 
22% (w/w) carbohydrate. PK-120 circulates in plasma at a con- 
centration of 80 ¢tg/ml, and it is easily degraded by a trace 
amount ofPK.  PK-120 is first cleaved by PK to yield a 100-and 
a 35-kDa fragments, and the resulting 100-kDa fragment is 
further converted to a 70-kDa fragment. However, the phys- 
iological role of PK-120 remains unclear. 
In this study, we have determined the entire amino acid 
sequence of human PK-120 by using recombinant DNA tech- 
niques, to assess the function of PK-120. The amino sequence 
suggested that PK-120 is closely related to heavy chains (HCs) 
of the inter-s-trypsin i hibitor (ITI) superfamily. Furthermore, 
the putative cleavage sites by PK have been found and the 
results predicted that PK-120 may be a precursor o fa  bioactive 
peptide. 
2. Materials and methods 
2.1. Materials 
Lysyl endopeptidase from Achromobacter lyticus M497-1 was ob- 
tained from Wako Pure Chemical Industries Ltd., Osaka. Restriction 
endonucleases and other DNA-modyfying enzymes were purchased 
from Takara Shuzo Co., Kyoto, Boehringer Mannheim GmbH, Ger- 
many, or New England Biolabs Inc., Beverly, MA. [~-~2P]dCTP was 
from DuPont-NEN Research Products, Boston, MA. Human liver 
poly(A) + RNA was a gift from Dr. F. Sakane (Sapporo Medical Col- 
lege, Japan). A human liver 2gtl 1 cDNA library was kindly provided 
by Prof. M. Tomita (Showa University, Japan). A Xgt 10 eDNA library 
of human liver was also used in this study and was purchased from 
Clontech, Palo Alto, CA. PK was purified from human plasma as 
previously described [9]. 
2.2. Determination f partial amino acid sequences ofPK-120 
PK-120 was purified from human plasma s reported by Pu et al. [8]. 
The purified material was incubated with PK and the resulting 70- and 
35-kDa fragments were isolated from the digest as previously described 
[8]. Both fragments were reduced, S-pyridylethylated, and then digested 
with lysyl endopeptidase [10]. The lysyl endopeptidase-digest was sepa- 
rated by reverse-phase high performance liquid chromatography on 
,uBondasphere S-5 C8 300A (2.1 x 150 mm; Waters, Millipore Corp., 
MA) and TSK-GEL ODS-120T (4.6 x 250 mm; Tosoh Corp., Tokyo) 
columns. The purified peptides were subjected to amino-terminal se- 
quence analysis on an Applied Biosystems model 477A gas-phase pro- 
tein sequenator/Applied Biosystems 120A PTH analyzer. 
2.3. Polymerase chain reaction (PCR) 
Based on the amino acid sequence (TGLLLLSDPD- 
KVTIGLLFWDGRGEGL) of the 35-kDa fragment-derived peptide, 
two degenerate oligonucleotides, 5'-GA(T/C)CC(G/AFF/C)GA(T/ 
C)AA(GIA)GT(G/A/TIC)AC(GIA/TIC)AT-3" and 5'-TC(G/A/T/ 
C)CC(GIAITIC)CG(GIA)CC(G/A)TCCCA(G/A)AA-3', were de- 
signed as PCR primers. First strand cDNA was synthesized from 0.1 
/~g of poly(A) + RNA of human liver with random primers, using a 
GeneAmp RNA PCR kit (Perkin-Elmer). The reaction mixture was 
used as a template for the following reaction. PCR (40 cycles) was 
performed using an AmpliTaq (Perkin-Elmer), with denaturation at 
94°C for 1 min, annealing at 50°C for 2 min, and extension at 72°C 
for 2 rain. The PCR product (50 bp) was subcloned into a pCRII vector 
(Invitrogen, San Diego, CA) and sequenced with an Applied Biosys- 
tems 373A DNA sequencer using the Dyedeoxy terminator cycle se- 
quencing kit (Applied Biosystems). 
*Corresponding author. Fax: (81) (11) 706-4990. 
Abbreviations." PK, plasma kallikrein; IT], inter-o-trypsin i hibitor; 
HC, heavy chain of the ITI superfamily; PCR, polymerase chain reac- 
tion; HA, hyaluronic acid. 
The nucleotide sequence data reported here will be available in the 
GenBank/EMBL nucleotide sequence databases with the accession 
number D38535. 
2.4. eDNA cloning of PK-120 
The cloned 50-bp DNA was labeled with [~-32p]dCTP by PCR as 
described above, and used to probe the human liver A, gtll eDNA 
library. The 2gt 10 cDNA library of human liver was secondly screened 
with the insert of the positive clone 2PK5, after labeling with 
[~-32P]dCTP using a Ready-To-Go DNA Labelling Kit (Pharmacia, 
Uppsala, Sweden). Hybridization was carried out at 60°C or at 65°C 
in a solution of 7% (w/v) polyethylene glycol 6000, 10% SDS and 100 
/tg/ml yeast tRNA, and washed with 2 x SSC (1 x SSC = 15 mM 
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Fig. 1. Restriction map and sequence strategy. The black box at the top shows the open reading frame. Each arrow indicates a direction and an 
analyzed area on a sequencing. 
sodium citrate and 150 mM NaC1, pH 7.0) containing 0.1% SDS at 
60°C or at 65°C. Inserts of the positive clones were subcloned into a 
pBluescript II SK- vector (Stratagene) and then sequenced in both 
directions by sequence-primer walking. 
2.5. Northern hlotting 
A Multiple Tissue Northern Blot (Clontech), to which poly(A) ÷ 
RNAs from various human organs were transferred, was hybrid- 
ized with a 32p-labeled BstXI fragment of 2PK67 in 5 x SSC, 10 × 
Denhardt's olution (1 × Denhardt's olution--0.02% polyvinyl- 
pyrrolidone, 0.02% bovine serum albumin and 0.02% Ficoll), 50 mM 
sodium phosphate (pH 6.8), 50% formamide and 100,ug/ml yeast RNA at 
42°C for 16 h and then washed in 0.1 x SSC containing 0.1% SDS at 
65 °C. The washed filter was subjected to autoradiography at -80 °C. 
2.6. Homology search 
The nucleotide and the deduced amino acid sequences were com- 
pared with all entries in the GenBank/EMBL Databases and the 
SWISS-PROT Protein Database, respectively, with the GENETYX- 
MAC system (Software Development Co., Tokyo). 
3. Resu l ts  
3.1. cDNA cloning of PK-120 
The amino acid sequences of several lysyl endopeptidase 
peptides derived from the 70- and the 35-kDa fragments were 
determined. A pair of oligonucleotide primers corresponding 
to the amino acid sequence of the 35-kDa fragment-derived 
peptide were used to amplify a partial cDNA fragment from 
human liver poly(A) ÷ RNA. PCR yielded a 50-bp cDNA frag- 
ment, and the deduced amino acid sequence of the fragment 
was identical to the peptide sequence. With the eDNA frag- 
ment, 6.5 x 105 independent clones of the human liver 2gt l l  
cDNA library were screened. Of 11 positive clones, the longest 
positive clone, 2PK5, was sequenced. This clone (1.7 kb) was 
shown to encode a carboxy-terminal portion of PK-120, a 
3' non-coding region, and a poly(A) tail (Fig. 1). To ob- 
tain clone(s) encoding the remaining part of PK-120, 1 × 106 
independent clones of the human liver Agtl0 cDNA library 
were also screened with the 32p-labeled 2PK5 insert. Of 106 
positive clones, the clone APK67 (3.0 kb) was sequenced. 
2PK67 encodes a 5' non-coding region and an amino-terminal 
portion of PK-120 including a putative signal sequence (Fig. 1). 
The composite nucleotide sequence obtained from these two 
clones spans 3,058 bp (not including a poly(A) tail) (Fig. 2). The 
ATG codon at nucleotide 130 begins an open reading frame of 
2,790 bp followed by a TAG termination codon. In the 3' 
non-coding region, there is one polyadenylation signal with the 
AATAAA sequence. The open reading frame encodes a puta- 
tive signal sequence of 28 amino acid residues and a mature 
protein of 902 amino acid residues, of which 211 residues were 
confirmed by the protein sequencing. The molecular mass of 
the mature protein without carbohydrate was calculated to be 
116,423 Da. There are four potential N-glycosylation sites 
(-Asn-Xaa-Ser/Thr-; Asn 53, Asn 179, Asn  489 and Asn549). Puta- 
tive cleavage sites by PK (-Phe-Arg-Xaa-) [11] have also been 
proposed (Arg 455, Arg 633 and Arg66°). 
3.2. Northern Blotting 
Northern blot analysis of poly(A) + RNAs of various human 
organs was carried out. As shown in Fig. 3, a band at 3.3 kb, 
in addition to a faint 4.0-kb band, was observed only in the 
poly(A) ÷ RNA of liver (lane 5). 
3.3. Homology search 
The nucleotide and the deduced amino acid sequences of 
PK- 120 cDNA were compared with all entries in the databases. 
These results indicated that PK-120 is highly homologous to 
HCs of the ITI superfamily. Fig. 4 shows an alignment of the 
amino acid sequences of PK-120 and the HCs. PK-120 exhib- 
ited significant sequence identities to HCI (34%) and HC2 
(31%) of human ITI and HC3 (38%) of human pre-~-trypsin 
inhibitor. Furthermore, an amino-terminal portion of PK-120 
____) 
Fig. 2. The composite nucleotide sequence (upper) and the deduced amino acid sequence (lower) of PK-120. A polyadenylation signal (AATAAA) 
is indicated by a thick underline. The amino acid residues confirmed by the protein sequencing are underlined. The putative cleavage sites by PK 
(-Phe-Arg-Xaa-) are marked by arrowheads. The potential N-glycosylation sites (-Asn-Xaa-Ser/Thr-) are shown by black circles. 
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Fig. 3. Northern blot analysis of PK-120 mRNA. A Multiple Tissue 
Northern Blot (Clontech), to which poly(A) + RNAs from various 
human organs were transferred, was hybridized with a riP-labeled 
BstXI fragment of tPK67. The organs analyzed here are as follows: 
lane 1, heart; lane 2, brain; lane 3, placenta; lane 4, lung; lane 5, liver; 
lane 6, skeletal muscle; lane 7, kidney; and lane 8, pancreas. For details 
see section 2. 
(residues 1 660) showed higher homologies to these proteins 
(HC1 40%, HC2 39%, and HC3 47%). ITI consists of two 
homologous HCs and one light chain including two Kunitz- 
type trypsin inhibitor domains (bikunin), and these were co- 
valently linked to a chondroitin sulfate. The amino acid se- 
quences of the HCs around the processing site for the chon- 
droitin sulfate binding are well conserved. Interestingly, the 
amino acid sequence of PK-120 corresponding to the process- 
ing site was completely different from those of the HCs. 
4. Discussion 
Here we have obtained two eDNA clones ( /PK5 and APK67) 
from human liver cDNA libraries and sequenced them. As 
shown in Fig. 3, an intense band at 3.3 kb was observed only 
in the poly(A) ÷ RNA of liver by using a 3ZP-labeled BstXI 
fragment of IPK67. A faint band at 4.0 kb, which may corre- 
spond to a PK-120-related molecule, was also observed in liver. 
These results suggested that the composite sequence of 3,058 
bp (not considering a poly(A) tail) obtained from these two 
clones covers almost the full-length PK-120 cDNA, and that 
PK-120 is mainly synthesized in liver. 
The deduced amino acid sequence of PK-120 indicated that 
it consists of 902 amino acid residues, of which 23% were 
confirmed at the protein level. Through the protein sequencing, 
Ser 66s, Thr 673, and Ser 674 could not be identified as phen- 
Hc3HC2HcIPK'120 (1-16)(1"108)(1"108)(1"96) SsiS ! _-_ ~EG.V~_  Z__ -  _~- _  .................................................................. 
PK.12o (,7.2o6  
HCI ( 109 -210 )[ ~ ~ Q / ~ L P ' - K ~ - [ ~ k ~ K K S F  SG . . . . . .  • " STS I~ ' -  
HC2 ( 109 -216 )~ ~ ~ ; -  -~V--PVI - SKGQ~~R__~C~C~ 
HC3 (117-211) /~C~L - G S~KS F SG I ¢ ~ ~ -  F~}TC~'~I~ 
HCI  ( 219- 329) - ~ I G H F ~ K I C D L L V A ~ ~ Z  ~ ~ / ~ .. • ~ ~]g~[ I~~VQ S[N~.C~lK~-d~Jg.~,~l~ S 
HC2 (217- 327)~-~D~E~LEV R ~ K ~ I  E~ 
HC3 ( 212" 3 2 2 ) "~DF2~]t~S l~tcWQ'r V ' ~ ~ ~ E ~ D V S 2 ~ ] K E ~ I ~ f - Q I ~ K 2 ~ K S  ME 
HC1 (330-438) L D ~ I ~ I E ~ - - - ~ V ~ S L P E L S ~ D P ~ D R S ~ I ~ ~  . . . . . . . .  " 
HC2 (328-436) PS ~ ~ I  F ~ - - ~ K L S ~ ~ ~ ~ [ ~ / f  S~g~%~4~ 













PK-120 (749-S49)KAGFSWI~-N- - -~SPEH~Rh~c~KWKETL~~Y~-K~LLLS~- -~T~- -~LFTKX~GLRLLL~RFSS~GGTLG Q 
HC I (751-045) LWSVDDG~GS~QDFLGF~g~DS~RTHGLLG~FH~IGFEVS~IH~SDPTK~~rVT- -~QKDYS-~ . . . . . . . . . . . . .  
. c2  (76z.sss) ~TLDK~SF.~S--~~F~IY£P~q~V~GLZGq~Q~t~I~__-R~P~X~SM~n~f4~IT--~kQXDYRT-gLV . . . . . . . . . . . .
H¢3 (730-S 26) mrVSFG~~DF~F~DSV~' r~Gu.G~VQ~S-~I~SD~~I~-  ~D~a-  ~SZ . . . . . . . . . . .  
PK-120 (850-902)FYQEV~PAASDDGRRTLRVQGNDHSATRERRLDYQEGPPG~--~L 
lIC1 (846-877) . . . . .  ~ A  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  ~C~F ~IHNNGAGL IDGAYTDY IVPDI F 
HC2 (856-809) . . . . . .  F~T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  DV~"~SGKGF I DGHYKDY FVPQLYS FLKRP 
HC3 (827-856) . . . . . . .  ~TK . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  V I~- INNG EG L I DGVH TDY I V PNL F 
Fig. 4. Alignment of amino acid sequences of PK-120 and HCs of the 1TI superfamily. Identical residues to those of PK-120 are boxed and shadowed. HC1, 
heavy chain 1 of human ITI [15,16]; HC2, heavy chain 2 of human ITI [16,17]; and HC3, a heavy chain of human pre-~-trypsin i hibitor [18]. 
A black arrowhead shows the PK-cleavage site of PK-120. An open arrowhead shows the processing site of the HCs for the chondroitin sulfate- 
binding. 
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ylthiohydantoin amino acids (Fig. 2). Since Pu et al. have sug- 
gested the existence of N- and O-linked sugar chains in PK-120 
[8], these amino acid residues are probably O-glycosylated. 
Furthermore, the potential N-glycosylation sites were identified 
(Asn 53, Ash 1v9, Asn 4s9 and Asn549): therefore at least one of them 
seems to be N-glycosylated. 
From the sequence data, it was found that PK-120 contains 
only three cysteine residues (Cys 386, Cys 719 and Cys 897) (Fig. 2). 
We have carried out the experiments of the titration for the 
SH-group on PK-120, 70- and 35-kDa fragments (data not 
shown). The results suggested that Cys 719 and Cys s97 form a 
disulfide bond within the 35-kDa fragment, and that Cys 386 is 
present as a free cysteine residue. 
On the protein-based study of PK-120, we could not identify 
a 30-kDa fragment, which should be released from the carboxy- 
terminal portion of the 100-kDa fragment, suggesting that the 
C-terminal 30-kDa region is degraded into small fragments [8]. 
The amino acid sequence of PK-120 predicted the putative 
cleavage sites of PK (-Phe-Arg-Xaa-; Arg 455, Arg 633 and Arg 66°) 
(Fig. 2). As for Arg 455, it is unclear whether this residue is a PK 
cleavage site or not. It is reasonable to consider that Arg 66° is 
one of the real PK cleavage sites, because the deduced amino 
acid sequence from Leu 662 is identical to the N-terminal se- 
quence of the 35-kDa fragment. In a previous study, the N- 
terminal residue of the 35-kDa fragment (corresponding to 
residue 661) was identified to be Asp [8], while the cDNA 
sequence data suggested that this residue is Arg. The reason for 
this discrepancy is unknown. Since the yield for a phenylthiohy- 
dantoin-Arg is very low on Edman degradation, residue 661 
may be Arg, rather than Asp. From these results, it is likely that 
a peptide of 27 amino acid residues (Pro634Arg 66°) is released 
from PK-120 by the PK digestion. The amino acid sequence of 
the carboxy-terminal portion of this peptide is similar to that 
of bradykinin released from high molecular weight kininogen 
by PK, suggesting that PK-120 may be a precursor of a bioac- 
tive molecule such as bradykinin. In fact, we could isolate this 
peptide from the PK digest of PK- 120 (data not shown). These 
results suggested that Arg 633 and Arg 66° are the PK cleavage 
sites and that this peptide is released from PK-120 by the PK 
digestion. The functional analysis of the peptide is actively 
ongoing in our laboratory. 
As shown in Fig. 4, a computer-assisted homology search 
indicated that PK-120 is closely related to HCs of the ITI 
superfamily. PK-120 showed high sequence homologies to HC 1 
(34%) and HC2 (31%) of human ITI and HC3 (38%) of human 
pre-c~-trypsin inhibitor. Interestingly, the 100- and the 70-kDa 
fragments are more homologous to the HCs than PK-120. 
Recently, it has been reported that bovine pre-~-trypsin i hib- 
itor (or ITI) stabilizes cumulus extracellular matrix, probably 
due to the binding of the protein to hyaluronic acid (HA) [12], 
and that the HCs of human and bovine ITIs act as HA-associ- 
ated proteins [13,14]. HA is a major component of extracellular 
matrix, which plays modulatory roles in tissue morphogenesis, 
cell migration, and cell proliferation. It is likely that the 100- 
and/or the 70-kDa fragments, rather than PK- 120, bind to HA, 
leading to the stabilization of extracellular matrix. In conclu- 
sion, the digestion of PK-120 by PK may be a important reac- 
tion for many fundamental biological processes as described 
above. 
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